Vaxcyte (PCVX) Other Operating Expenses (2022 - 2023)
Vaxcyte's (PCVX) quarterly Other Operating Expenses came in at $75.0 million in Q4 2023, up 226.16% year-on-year from $23.0 million in Q4 2022, and up 226.16% on a QoQ basis from $23.0 million in Q4 2022.
Vaxcyte (PCVX) Other Operating Expenses (2022 - 2023) Analysis & Trends
Vaxcyte (PCVX) has 2 years of Other Operating Expenses data on file, last reported at $75.0 million in Q4 2023.
- On a quarterly basis, Other Operating Expenses rose 226.16% year-over-year to $75.0 million in Q4 2023; TTM through Sep 2024 was $75.0 million, a 226.16% increase from a year earlier, with the FY2022 full-year figure at -$44000.0, changed N/A from the prior year.
- Other Operating Expenses for Q4 2023 stood at $75.0 million, up from $23.0 million in the prior quarter.
- Over the last five years, Other Operating Expenses for PCVX reached as high as $75.0 million in Q4 2023 and fell as low as $23.0 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Vaxcyte | 7.76 Bn | 7.76 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 75.00 Mn |
| Dec 31, 2022 | 23.00 Mn |